Capsule Pathology

After explant surgery, the capsule and any unusual fluid are sent for pathological examination. This is not an optional step — it is part of evidence-based surgical care, particularly for patients with textured implants, swelling, or unexplained symptoms.

Capsule pathology is the microscopic examination of breast implant capsule tissue after explantation surgery. It is the standard of care for breast implant removal in 2026 — particularly for textured implants — enabling early detection of BIA-ALCL, characterization of inflammation patterns, and identification of bacterial biofilm or atypical findings that inform follow-up care.

What is capsule pathology?

The capsule is the layer of scar tissue your body forms around any breast implant. After surgical removal, the capsule tissue is sent to a pathologist who:

• Examines tissue microscopically
• Identifies cell populations (lymphocytes, inflammatory infiltrates, atypical cells)
• Performs immunohistochemistry if abnormalities suggest BIA-ALCL
• Reports findings to the surgeon and patient

Why it matters

BIA-ALCL screening

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare lymphoma associated primarily with textured breast implants. Early detection via capsule and fluid pathology saves lives. Without pathology, it can be missed.

Atypical findings

Sometimes pathology reveals findings that warrant follow-up:

• Inflammatory patterns suggesting chronic immune response
• Foreign body reactions
• Calcifications
• Other rare findings (epithelial inclusions, etc.)

Peace of mind

For patients who chose explant due to BII concerns, a clear pathology report provides reassurance. A pathology report showing inflammation can also validate the symptoms the patient was experiencing.

What to ask your surgeon

What happens if findings are abnormal?

If pathology reveals BIA-ALCL or other concerning findings:

1. The surgeon discusses results with the patient
2. Referral to a hematologist-oncologist with BIA-ALCL experience
3. Staging studies (PET, bone marrow) may be needed
4. For early-stage BIA-ALCL confined to the capsule, complete capsulectomy alone is often curative
5. Advanced cases may need chemotherapy or other treatments

FDA and EMA guidance

The US FDA and European Medicines Agency both recommend pathological analysis of implant capsules in explant surgery, particularly for textured implants. This is established standard of care.